Delaware-based Precision BioSciences has terminated an undisclosed number of employees in order to extend its cash runway into the second half of 2027.
All entries for: Chronic Disease
August 8, 2025
Precision BioSciences
Layoffs
Durham, NC
51-200 employees
Disease Area: Chronic Disease, Hematology, Infectious Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
July 24, 2025
Tessera Therapeutics
Layoffs
Somerville, MA
201-500 employees
Tessera Therapeutics will reduce its workforce by 17%, according to reporting from Fierce Biotech, which confirmed the layoffs with a company spokesperson. The move will help support Tessera’s transition into clinical work later this year. It is unclear when the layoffs will take effect or how many exactly will be affected.
Disease Area: Chronic Disease, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic
July 24, 2025
Hyperion Defi Inc
Negative Outlook
Laguna Hills, CA
1-50 employees
We expect that federal, state and local governments in the United States, as well as foreign governments, will continue to consider legislation directed at lowering the total cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize any product that is ultimately approved, if approved. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.
Disease Area: Chronic Disease, Multiple, Neurological Diseases
Drug Type: Small Molecule
July 18, 2025
Sarepta Therapeutics
Layoffs
Cambridge, MA
1,001-5,000 employees
After a difficult season that has seen two deaths linked to Sarepta Therapeutics’ Duchenne muscular dystrophy treatment Elevidys, the Cambridge, Massachusetts–based biotech is letting go of more than a third of its workforce and adding a black box warning for acute liver injury and acute liver failure to the gene therapy. In a July 16 announcement, Sarepta revealed it will part with around 500 employees after a strategic review and focus its pipeline on “high-impact programs, prioritizing potentially best-in-class siRNA platform assets.” These include programs for facioscapulohumeral muscular dystrophy, idiopathic pulmonary fibrosis and Huntington’s disease.
Disease Area: Chronic Disease, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
July 9, 2025
Jasper Therapeutics
Layoffs
Redwood City, CA
51-200 employees
After “issues” with a batch of its investigational antibody briquilimab “confounded” the readout of Jasper Therapeutics’ Phase Ib/IIa BEACON study in chronic spontaneous urticaria (CSU), the California-based biotech is laying off approximately half of its staff.
Disease Area: Chronic Disease, Hematology, Immune Diseases, Multiple
Drug Type: Biologic
July 1, 2025
Kalaris Therapeutics
Negative Outlook
Palo Alto, CA
1-50 employees
In August 2022, the IRA was signed into law. The IRA includes several provisions that could impact AlloVir’s business to varying degrees, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA’s Medicare drug price negotiation program. The effect of IRA on AlloVir’s business and the healthcare industry in general is not yet known.
Disease Area: Chronic Disease, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
June 16, 2025
Gilead Sciences - Oceanside
Layoffs
Oceanside, CA
10,001-50,000 employees
Gilead Sciences cut 36 employees in Oceanside, California, effective Aug. 15, according to a Worker Adjustment and Retraining Notification notice. The location supports clinical manufacturing and process development for the Foster City, California–based pharma and subsidiary Kite Pharma.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
June 10, 2025
SciSparc
Neutral Outlook
Tel Aviv, Israel
1-50 employees
The passage of the Inflation Reduction Act, or the IRA, of 2022 further affects Medicare reimbursement. The IRA has three key elements reforming Medicare drug-pricing policy. The implementation of certain elements of the IRA are still forthcoming, as outlined below, so the specific implications for biopharmaceutical pricing and reimbursement are yet to be determined. Likewise, SciSparc is unable to predict potential modification, amendment, or repeal of the IRA, though some predict that challenges may be made as different provisions are enacted.
Disease Area: Chronic Disease, Multiple, Neurological Diseases, Psychiatry, Respiratory Diseases
Drug Type: Small Molecule
June 6, 2025
Dr. Reddy's Laboratories
Neutral Outlook
Princeton, NJ
10,001-50,000 employees
“For example, in the United States, Congress passed the Inflation Reduction Act of 2022 (the “IRA”), which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of new rebates and financial penalties for drugs (including single-source generics) whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028. The long-term implications of the IRA remain uncertain and we are continuing to evaluate this law and its impact on our business.
“
Disease Area: Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 27, 2025
Channel Therapeutics
Negative Outlook
North Brunswick, NJ
1-50 employees
Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the American Rescue Plan Act of 2021, which eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. In addition, the Inflation Reduction Act of 2022 (“IRA”) which among other things, extended enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminated the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have an adverse effect on customers for ZELSUVMI and our product candidates, if approved, and, accordingly, our financial operations.
Disease Area: Chronic Disease, Multiple, Neurological Diseases
Drug Type: Small Molecule
